.png){kind=logo}
Botanical Innovation for Cancer Care
​
From improving quality of life during chemotherapy to investigating better outcomes in advanced cancers, NatureCeuticals is developing clinically evaluated botanical medicines designed to complement modern oncology treatment.
Advancing a New Generation of Botanical Oncology Medicines
NatureCeuticals is developing standardized, pharmaceutical-grade botanical medicines for supportive and adjunctive cancer care. Our lead product, Nuvastatic™, has completed Phase III evaluation for cancer-related fatigue in breast cancer patients undergoing chemotherapy and is now being studied alongside standard chemotherapy in metastatic colorectal cancer and metastatic triple-negative breast cancer.
With established hospital use in supportive care and a growing body of clinical, preclinical and patient evidence, Nuvastatic™ represents a broader approach to cancer care—supporting patients through treatment while investigating its potential to improve clinical outcomes.
Research
Advancing a New Generation of Botanical Oncology Medicines
Advancing the Future of Oncology Supportive Care
NatureCeuticals is a clinical-stage oncology biotechnology company dedicated to developing evidence-based botanical medicines that improve the lives of people living with cancer. Through rigorous translational research, pharmaceutical development, and multicentre randomized controlled clinical trials, we are advancing innovative botanical therapies that complement modern cancer treatment.
To date, approximately 800 patients have participated in randomized controlled clinical studies evaluating our lead botanical medicine, Nuvastatic™, with more than 500 additional patients currently enrolled in ongoing Phase III clinical trials across multiple cancer indications.
Our mission is to deliver scientifically validated botanical therapeutics that improve quality of life, reduce the burden of treatment-related side effects, and support patients throughout their cancer journey.
Clinical Milestones
Nuvastatic™ Phase III Clinical Trial Successfully Completed
Nuvastatic™ has successfully completed a pivotal Phase III randomized, double-blind, placebo-controlled clinical trial in Stage I–III breast cancer patients undergoing first-line chemotherapy. The study demonstrated significant improvements in cancer-related fatigue and health-related quality of life, representing an important milestone in the clinical development of evidence-based botanical medicines for oncology supportive care.
Current Clinical Development Program
NatureCeuticals continues to expand the clinical evaluation of Nuvastatic™ through ongoing Phase III studies designed to address important unmet needs in oncology.
-
Advanced Metastatic Colorectal Cancer (Stage IV)
Evaluation of cancer-related fatigue, health-related quality of life, and treatment tolerability in patients receiving standard chemotherapy. (Study nearing completion.) -
Advanced Metastatic Colorectal Cancer (Stage IV)
Evaluation of tumour response, progression outcomes, cancer-related fatigue, and quality of life in combination with standard chemotherapy. -
Metastatic Triple-Negative Breast Cancer (Stage IV)
Evaluation of tumour response, cancer-related fatigue, quality of life, and clinical outcomes in patients receiving standard chemotherapy.
Through these clinical development programmes, NatureCeuticals is building one of the world's most comprehensive clinical evidence portfolios for botanical medicines in oncology supportive care, with the vision of integrating scientifically validated botanical therapeutics into modern cancer care.
Advancing a New Generation of Botanical Oncology Medicines
Advancing the Future of Oncology Supportive Care
NatureCeuticals is a clinical-stage oncology biotechnology company dedicated to developing evidence-based botanical medicines that improve the lives of people living with cancer. Through rigorous translational research, pharmaceutical development, and multicentre randomized controlled clinical trials, we are advancing innovative botanical therapies that complement modern cancer treatment.
To date, approximately 800 patients have participated in randomized controlled clinical studies evaluating our lead botanical medicine, Nuvastatic™, with more than 500 additional patients currently enrolled in ongoing Phase III clinical trials across multiple cancer indications.
Our mission is to deliver scientifically validated botanical therapeutics that improve quality of life, reduce the burden of treatment-related side effects, and support patients throughout their cancer journey.
Clinical Milestones
Nuvastatic™ Phase III Clinical Trial Successfully Completed
Nuvastatic™ has successfully completed a pivotal Phase III randomized, double-blind, placebo-controlled clinical trial in Stage I–III breast cancer patients undergoing first-line chemotherapy. The study demonstrated significant improvements in cancer-related fatigue and health-related quality of life, representing an important milestone in the clinical development of evidence-based botanical medicines for oncology supportive care.
Current Clinical Development Program
NatureCeuticals continues to expand the clinical evaluation of Nuvastatic™ through ongoing Phase III studies designed to address important unmet needs in oncology.
-
Advanced Metastatic Colorectal Cancer (Stage IV)
Evaluation of cancer-related fatigue, health-related quality of life, and treatment tolerability in patients receiving standard chemotherapy. (Study nearing completion.) -
Advanced Metastatic Colorectal Cancer (Stage IV)
Evaluation of tumour response, progression outcomes, cancer-related fatigue, and quality of life in combination with standard chemotherapy. -
Metastatic Triple-Negative Breast Cancer (Stage IV)
Evaluation of tumour response, cancer-related fatigue, quality of life, and clinical outcomes in patients receiving standard chemotherapy.
Through these clinical development programmes, NatureCeuticals is building one of the world's most comprehensive clinical evidence portfolios for botanical medicines in oncology supportive care, with the vision of integrating scientifically validated botanical therapeutics into modern cancer care.
Advancing a New Generation of Botanical Oncology Medicines
Advancing the Future of Oncology Supportive Care
NatureCeuticals is a clinical-stage oncology biotechnology company dedicated to developing evidence-based botanical medicines that improve the lives of people living with cancer. Through rigorous translational research, pharmaceutical development, and multicentre randomized controlled clinical trials, we are advancing innovative botanical therapies that complement modern cancer treatment.
To date, approximately 800 patients have participated in randomized controlled clinical studies evaluating our lead botanical medicine, Nuvastatic™, with more than 500 additional patients currently enrolled in ongoing Phase III clinical trials across multiple cancer indications.
Our mission is to deliver scientifically validated botanical therapeutics that improve quality of life, reduce the burden of treatment-related side effects, and support patients throughout their cancer journey.
Clinical Milestones
Nuvastatic™ Phase III Clinical Trial Successfully Completed
Nuvastatic™ has successfully completed a pivotal Phase III randomized, double-blind, placebo-controlled clinical trial in Stage I–III breast cancer patients undergoing first-line chemotherapy. The study demonstrated significant improvements in cancer-related fatigue and health-related quality of life, representing an important milestone in the clinical development of evidence-based botanical medicines for oncology supportive care.
Current Clinical Development Program
NatureCeuticals continues to expand the clinical evaluation of Nuvastatic™ through ongoing Phase III studies designed to address important unmet needs in oncology.
-
Advanced Metastatic Colorectal Cancer (Stage IV)
Evaluation of cancer-related fatigue, health-related quality of life, and treatment tolerability in patients receiving standard chemotherapy. (Study nearing completion.) -
Advanced Metastatic Colorectal Cancer (Stage IV)
Evaluation of tumour response, progression outcomes, cancer-related fatigue, and quality of life in combination with standard chemotherapy. -
Metastatic Triple-Negative Breast Cancer (Stage IV)
Evaluation of tumour response, cancer-related fatigue, quality of life, and clinical outcomes in patients receiving standard chemotherapy.
Through these clinical development programmes, NatureCeuticals is building one of the world's most comprehensive clinical evidence portfolios for botanical medicines in oncology supportive care, with the vision of integrating scientifically validated botanical therapeutics into modern cancer care.
Supportive Cancer Care Solutions
From treatment support and symptom management to nutritional care, NatureCeuticals is developing innovative evidence-based botanical solutions to improve outcomes and quality of life for cancer patients.
1
Adjunctive Therapeutics
Nuvastatic™ 300
A proprietary nano-formulated botanical medicine being developed as an adjunctive therapy for cancer treatment. Nuvastatic™ 300 is currently undergoing Phase III clinical evaluation in patients with advanced metastatic breast cancer and advanced metastatic colorectal cancer.
The program is designed to support treatment outcomes while maintaining an excellent safety profile through a scientifically standardised rosmarinic acid-rich botanical formulation.
Status: Phase III Clinical Development
Cancer Supportive Care
Nuvastatic™
A clinically validated botanical medicine developed to reduce cancer-related fatigue and improve quality of life in patients undergoing cancer treatment.
Nuvastatic™ has successfully completed Phase III clinical evaluation in breast cancer patients receiving chemotherapy and is currently being further evaluated in additional oncology populations.
The program aims to help patients maintain physical function, wellbeing, and treatment adherence throughout their cancer journey.
​
2
3
Oncology Nutrition Support
Nuvastatic Life™
An oncology-focused nutritional support program combining Nuvastatic active ingredients, Lanctos 75™, vitamins, minerals, and essential nutrients to support the nutritional needs of cancer patients.
Developed to complement supportive care strategies, Nuvastatic Life™ is designed to help patients maintain nutritional status, strength, and quality of life during treatment and recovery.
​
Our Story
Get to Know Us
NatureCeuticals was founded to transform botanical science into clinically validated medicines that improve the lives of cancer patients.
Building on decades of research in natural product pharmacology, we have developed a portfolio of oncology-focused programs spanning cancer therapeutics, supportive care, and nutritional support. From laboratory discovery to Phase III clinical studies, our mission is to deliver innovative, evidence-based botanical solutions that address unmet needs in cancer care.
